Table 3.
Characteristics of patients divided by groups
| Group | A | B | C | D | E | χ2/Kruskall Wallis |
| SVR | NR | Mild recurrence | Too sick | Comorbidity | ||
| n | 63 | 87 | 73 | 35 | 100 | |
| Gender (M/F) | 47/16 | 73/14 | 63/10 | 20/15 | 78/22 | P = 0.007 |
| Age at LT (yr, mean ± SD) | 52 ± 8 | 52 ± 9 | 53 ± 8 | 52 ± 9 | 51 ± 9 | P = NS |
| Donor age (yr, mean ± SD) | 49 ± 17 | 56 ± 15 | 48 ± 17 | 59 ± 15 | 55 ± 17 | P = 0.001 |
| HCV genotype | P = NS | |||||
| 1 | 37 | 60 | 45 | 16 | 44 | |
| 2 | 7 | 6 | 9 | 3 | 13 | |
| 3 | 9 | 13 | 6 | 5 | 14 | |
| 4 | 8 | 5 | 7 | 1 | 10 | |
| Immunosuppression | 48 | 55 | 54 | 24 | 83 | P = NS |
| Cyclosporine | 14 | 31 | 16 | 10 | 13 | |
| Tacrolimus | 1 | 1 | 3 | 1 | 4 | |
| Other regimens | ||||||
| Time between treatment start and LT [mo, median (min-max)] | 20 (1-148) | 16 (1-117) | P = NS | |||
| Treatment Length [mo, median (min-max)] | 11 (1-61) | 6 (1-63) | P = 0.010 |
SVR: Sustained virological response; NR: Non-response; HCV: Hepatitis C virus; NS: Not significant; LT: Liver transplantation.